Home > Neurology > AAN 2022 > Multiple Sclerosis > Favourable additional safety data for ofatumumab

Favourable additional safety data for ofatumumab

Presented By
Prof. Stephen Hauser, University of California, CA, USA
AAN 2022
After up to 4 years of treatment, ofatumumab was still well tolerated in patients with relapsing multiple sclerosis (RMS); no new safety issues were identified. This was concluded from updated results of the ongoing, open-label, umbrella extension ALITHIOS trial. Ofatumumab is a fully-human, anti-CD20 monoclonal antibody developed for the treatment of adult RMS patients; the 20 mg dose is self-administered subcutaneously once a month [1]. Ofatumumab treatment up to 30 months was previously shown to have a favourable safety profile and to be generally well tolerated [2]. Cumulative data for up to 4 years of ofatumumab treatment were presented by Prof. Stephen Hauser (University of California, CA, USA) [3,4]. Patients had completed the core ASCLEPIOS I/II (NCT02792218,

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on